QPS Announces the Opening of its New In Vitro Dermal & Transdermal Research Laboratory in Fargo, North Dakota


QPS Holdings, LLC, a leading full-service contract research organization, announces the opening of its new in vitro dermatology and transdermal research laboratory in Fargo, North Dakota. This new physical extension of QPS’ Dermal and Transdermal Research Services portfolio will further strengthen QPS’ ability to assist clients in quickly moving their dermal and transdermal products from pre-clinical evaluations through to late stage clinical development.

“With QPS’ increasing early phase clinical presence in topical and transdermal pharmacokinetics and bioequivalence, this is a logical step in the evolution of our Dermal and Transdermal Research Services Division,” said Ben Chien, PhD, QPS President and CEO. “Our Dermal and Transdermal Research Services Division, which has been embraced by the industry since its establishment under the leadership of Paul Lehman, has quickly become a major asset to QPS - and crucial for the future success for our clients.”

The laboratory will be directed by Paul A. Lehman, MSc, Vice President and Head of QPS Dermal and Transdermal Research Services. This research facility is backed by 36 years of topical pharmacokinetics experience with the Franz Diffusion Cell. This model and associated methodologies support dermal drug development testing in the preclinical, clinical, and post-approval phases, including the in vitro rate-of-release assay based on the FDA SUPAC-SS Guidance.

As of May 1st, 2015 the new in vitro dermatology and transdermal laboratory in Fargo, North Dakota is offering its services to clients conducting in vitro Research & Development (non-GLP) topical pharmacokinetics and in vitro release rate studies using the Franz Diffusion Cell. The laboratory will also be offering augmenting services for studies intended for regulatory submission (with full GLP compliance).

20 years in pharma R&D navigation